



PGDIS CONFERENCE




6-8 May 2024
Kuala Lumpur
Malaysia

**PGT and
BEYOND...**

Noninvasive PGT: 8 years of clinical applications

Sijia Lu

7th, May, 2024





|| Cofounder and CEO of Yikon Genomics

PGT and
BEYOND...

| Main Contents

01
PART



NICS Development

02
PART



NICS Accuracy Validations

03
PART




Clinical Studies and Applications

04
PART



Limitation & Future Prospect

Noninvasive chromosome screening (NICS) Development



NICS Development



NICS baby born in Wuxi, China

Performance	Number	Ratio (%)
Sensitivity	15/17	88.2%
Specificity	21/25	84.0%
PPV	15/19	78.9%
NPV	21/23	91.3%

PPV: pos. predictive value; NPV: neg. predictive value

Table 2. Clinical outcome of the first seven patients subjected to NICS

Patient no.	Maternal age	Clinical indications	Transfer cycles	Clinical outcome
P01	30	Reciprocal translocation 46,XY,t(14;15)	1	Singleton pregnancy—live birth
P02	28	Azoospermia	1	Singleton pregnancy—live birth
P03	34	Inversion 46,XY,inv(9)	1	Singleton pregnancy—live birth
P04	32	Reciprocal translocation 46,XX,t(1;18)	2	Implantation failure
P05	26	Recurrent pregnancy loss	1	Singleton pregnancy—live birth
P06	32	47,YYY	2	Singleton pregnancy—live birth
P07	29	Recurrent implantation failure	1	Singleton pregnancy—following up

- **Sample size:** 52 donated frozen blastocysts
- **Validation method:** Whole embryo as a gold standard
- **Conclusion:** NiPGT-A is more reliable than TE-biopsy PGT-A in frozen-thawed embryos.





Fig. 2. Workflow of sample processing for PGT-A analysis of TE biopsy, embryo, and spent culture media.

Table 2. Comparison of the performance of niPGT-A versus TE biopsy for PGT-A

Performance characteristic	niPGT-A (n = 48)	TE-biopsy (n = 50)
FPR	20.0% (3/15)	50.0% (9/18)
FNR	0.0% (0/33)	0.0% (0/32)
PPV	91.7% (33/36)	78.0% (32/41)
NPV	100.0% (15/15)	100.0% (18/18)
Sensitivity	100.0% (33/33)	100.0% (32/32)
Specificity	80.0% (12/15)	50.0% (9/18)
% Concordance for embryo ploidy	93.8% (45/48)	82.0% (41/50)
% Concordance for chromosome CNs	83.3% (40/48)	62.0% (31/50)

niPGT-A and TE biopsy results were compared with those of the embryo. Sequencing threshold was set at 60% mosaicism.

- **Sample size:** 265 donated embryos
- **Validation method:** Whole embryo as a gold standard
- **Conclusion:** Accuracy of NICS comparable to TE-PGT




Assay	Sensitivity % (95% CI)	Specificity% (95% CI)	NPV (95% CI)	PPV (95% CI)
TE-PGT	89.6(81.9-94.2)	80.0(73.1-85.5)	92.8(87.2-96.0)	72.9(64.2-80.1)
NICS	86.5(78.2-91.9)	73.1(65.8-79.4)	90.0(83.6-94.1)	65.9(57.2-73.6)
<i>P</i>	0.6291	0.1524	0.5144	0.2677



- **Sample size:** 41 frozen donated blastocysts
- **Validation method:** Whole embryo as a gold standard

NICS CNV are highly concordant with biopsied based PGT-SR



Trophectoderm

Blastocyst-stage embryos

Blastocyst culture medium

Comparison of results from TE and SCM to embryos: red highlights the duplication and blue highlights the deletion related to translocation.



- 345 paired blastocyst culture medium and whole blastocyst samples
- Embryos were graded as A, B or C according to their euploidy probability levels





Figure A: NICS grading distribution of grade A, B and C

Figure B: Grade A 91.4% Euploid; Grade B 76.4% Euploid ; Grade C 34.6% Euploid

NICS AI grading system using the machine learning method.



Patients with RPL (≥ 3 times) or RIF (≥ 3 times).

A total of 52 euploid embryos were transferred in
43 RPL or RIF patients.

Table 3 Pregnancy outcomes with NICS


	Chromosomal rearrangement	Normal karyotype	Total
Total ET			
Cycles	25	25	50
Patients	22	21	43
(SET/DET)	25/0	23/2	48/2
Transferred euploid blastocysts	25	27	52
Biochemical pregnancies	68% (17/25)	76% (19/25)	72.0% (36/50)
Clinical pregnancies	52% (13/25)	64% (16/25)	58.0% (29/50)
Miscarriages	15.4% (2/13)	6.2% (1/16)	10.3% (3/29)
Deliveries	11	15	26
Singleton/twins	11/0	14/1	25/1
Babies born (male/female)	11 (6/5)	16 (9/7)	27 (15/12)
Birth weight (g, mean \pm SD)	3283.7 \pm 412.4	3174.7 \pm 391.5	3217.5 \pm 403.4

DET, double embryos transfer; ET, embryo transfer; NICS, non-invasive chromosome screening; SET, single embryo transfer

A total of 27 healthy babies were delivered.


Patients with subclinical RPL and RIF

A total of 273 women with a history of RPL or RIF



Patients with RPL ≥ 2 times or once with abnormal product of conception.

Reduce the incidence of miscarriage
Increase ongoing pregnancy rate



Patients with RIF ≥ 2 times

Increase the clinical pregnancy rate

- 212 frozen-thawed single-blastocyst transfers based on morphological grades
- SCM collection in preincubation for 6 h after thawing






Fig. 1 Flowchart of the study. Patients implanted with single frozen blastocysts selected based on morphological quality



The pregnancy rates were significantly higher in both the euploidy and N/A groups compared to the aneuploidy group.



- Failed sperm DNA amplification in the current amplification system
- No paternal contamination was observed in conventional IVF SCM.
- IVF NICS performances \approx ICSI.

	Concordance	Sensitivity	Specificity	PPV	NPV
IVF-Adjusted	75%(108/144)	91.38%(53/58)	63.95%(55/86)	63.1%(53/84)	91.67%(55/60)
ICSI-Adjusted	74.58%(88/118)	84.21%(48/57)	65.57%(40/61)	69.57%(48/69)	81.63%(40/49)
P-Value	0.94	0.24	0.84	0.40	0.12

Embryo Transfer Prioritization

- ESNi-PGT (Embryo Selection by Noninvasive Preimplantation Genetic Test, NCT04339166)

ClinicalTrials.gov PRS
Protocol Registration and Results System

Contact ClinicalTrials.gov PRS
Org: PekingUTH User: JQiao Logout

Home > Record Summary

ID: ESNi-PGT Embryo Selection by Noninvasive Preimplantation Genetic Test NCT04339166

Record Summary

Home Help

Record Status


In Progress ➡ Entry Completed ➡ Approved ➡ Released ➡ PRS Review ➡ **Public**

[Reset to In-Progress...](#)

Record Owner: JQiao	Access List: Edit
Last Update: 04/03/2020 03:50 by JQiao	Upload: Allowed Edit
Initial Release: 04/01/2020	PRS Review: Review History
Last Release: 04/07/2020 Receipt (PDF)	Public Site: Last Public Release: 04/07/2020 View on ClinicalTrials.gov
FDAAA: Non-ACT (No FDA-regulated drug/device)	

1148 couples aged 35~42 (women) are planned to be enrolled from 13 IVF centers in China mainland.

**finished recruiting patients in 2023
result unblinded April 2024.**



A Double-blind, randomised controlled trial



Clinical Usage/Benefits

- Clinical NICS usage: >50000 tests from ~230 centers in the past 5 years as a supplement to PGTA.
- For all IVF cycles? Probably not for now.
- For patients with increased risk of embryo aneuploidy (in China, ≥ 2 failed implantations and ≥ 1 miscarriage, or >35 maternal age)
- Reanalyze frozen embryos (D5 thawed for 6-8 hours, <5% no call, >93% concordance)
- For embryos with poor morphology
- Embryo biopsy limited by expertise or regulation.



Limitations and Future directions

- Accuracy: Susceptible to sample contamination (cumulus, polar body, external contaminations): recommend to check SNP, especially for embryos with euploid results.
NOT a diagnostic test as of now.
- Sensitivity: D5 no call rate: ~10-15%, ~80% concordance, D6 embryos are more accurate, <5% no call rate, ~90% concordance... But should D5 embryos be cultured to D6?
- Standardization: automation
- PGTM and PGTSR?
- Need more research on the origin of contamination. (methylation? SNP? transcriptomics?)



Acknowledgements

- *Prof. X. Sunney Xie of Harvard University and Peking University*
- *Prof. Jie. Qiao and ESNI-PGT Clinical Trial Project Team*
- *Dr. Catherine Racowsky of Brigham and Women's Hospital, Harvard University*
- *Dr. Cai Liyi of Hebei Maternity Hospital*
- *Dr. Yao Bing of Eastern Theater Command General Hospital*
- *Dr. Wang Xiuxia of Shengjing Hospital, Shenyang*
- *.....*

THANK YOU

**PGT and
BEYOND...**